Sign Up
|
Sign In
Home
US Market
UK Market
News
My Portfolio
Forex
Forum
Cockpit
EuroTrader
Home
»
World
»
North America
»
United States
»
Biotechnology
»
Celgene Corporation
Celgene Corporation
CELG
(NASDAQ)
Overview
Discussions
Advanced chart
News
Historical data
Recommendations
To view this page ensure that Adobe Flash Player version 10.0.0 or greater is installed.
Industry
:
Health Care
Sector
:
Pharmaceuticals & Biotechnology
$
69.42
Updated
00:30:02
Change %
1.9%
Change
1.3200
Volume
2,469,235
High
$
69.51
Low
$
68.10
Open
$ 68.11
Prev close
$ 68.10
# of shares
-
Market cap
-
Intraday
Market closed
Tech analysis
Market is closed, opens at 14:30
Price development
Latest
1 week
1 month
3 mon
6 mon
1 year
69.42
-2.5%
-12.2%
-7.0%
12.5%
14.8%
Insufficient flash player version
News about Celgene Corporation
Subscribe To RSS Feed
Local
International
Announcements
07 May
FDA: Celgene Drug Revlimid Increases Risk Of Certain New Cancers
26 April
Celgene 1Q Profit Rose 57% On Sales Growth; Plans Venture With Epizyme
26 April
TIP SHEET: Janus Fund Tries To Manage Risk Of Drug Stocks
25 April
TIP SHEET: Janus Fund Tries To Manage Risk Of Drug Stocks
21 April
MARKET SNAPSHOT: U.S. Stock Gains Hinge On Apple, Blue-chip Results
17 April
EARNINGS PREVIEW: US Biotechs' 1Q To Focus On Deals, Pipelines
12 April
Drug Executives Tout R&D Spending As Industry Hits Patent Cliff
17 February
Vidaza® reçoit un avis définitif positif de la part du National Institute for Health and Clinical Excellence (NICE) pour être ut
03 February
Zacks Sell List Highlights: Greenhill & Co, Electronic Arts, AMCOL International and Celgene
24 January
Critical Alerts for General Electric, Novellus, Celgene, Motorola Solutions, and Copart Released by Seven Summits Research
11 January
Zacks Analyst Blog Highlights: The Coca-Cola Company, DuPont Fabros Technology, United Parcel Service, Caterpillar and Celgene
06 January
Celgene annonce le dépôt de soumissions réglementaires
15 December
Critical Alerts for AT&T, Tyco International, Adobe Systems, Baxter International, and Celgene Released by Seven Summits Res
08 December
Une étude observationnelle ne démontre aucune incidence accrue de progression vers la leucémie myéloïde aiguë avec REVLIMID® che
07 December
L'analyse rétrospective des données cliniques de l'étude de phase III portant sur le REVLIMID®(MDS-004) signale une amélioration
07 December
Présentation à l'ASH des données cliniques de deux études de phase II évaluant l'administration de REVLIMID® en association avec
07 December
Les données de trois présentations évaluant les bienfaits cliniques du Pomalidomide chez les patients atteints de myélome multip
No news for this instrument
More news
Company profile
No description
Version: LiveBranchBuild_20120516.1 - EUROWEB1 - 2012-05-22 02:08:31 - 2012-05-22 01:08:31 - 1000 - Website: OKAY